Survey of Cannabinoid Trials in Neurology: Promising but Unstandardized

A registry-based systematic mapping review of ClinicalTrials.gov identifies 47 completed cannabinoid trials across neurological conditions, revealing growing clinical interest concentrated in Multiple Sclerosis, fibromyalgia, and Parkinson’s Disease, but significant methodological fragmentation that prevents any pooled efficacy conclusions.

Why This Matters

Patients with chronic neurological conditions increasingly ask about cannabinoids, and clinicians need to know where the evidence actually stands. The number of registered cannabinoid trials in neurology has grown substantially, yet the field lacks a clear map of what has been tested, in whom, and with what rigor. This review arrives at a moment when commercial enthusiasm far outpaces clinical certainty, making an honest inventory of trial activity, and its limitations, especially valuable for guiding both practice and future research investment.

Clinical Summary

Cannabinoids, primarily THC and CBD, have plausible mechanisms of action in neurological conditions through their interaction with the endocannabinoid system, which modulates pain signaling, neuroinflammation, spasticity, and neuronal excitability. This registry-based systematic mapping review, published in 2025, searched ClinicalTrials.gov to characterize the landscape of completed clinical trials examining cannabinoids for neurological disorders. Starting from over 507,000 registry records, the authors progressively filtered to 132 cannabinoid-relevant neurological trials and ultimately included 47 that met criteria for completion status, cannabinoid as primary intervention, and clearly defined primary outcomes.

The 47 included trials were predominantly Phase 2, with Multiple Sclerosis, fibromyalgia, and Parkinson’s Disease the most frequently studied conditions. Primary outcomes clustered around pain management, spasticity, and cognitive function, with safety and tolerability as common secondary endpoints. Critically, the review performed no meta-analysis, no risk-of-bias assessment, and drew from a single trial registry. The authors’ language about “promising results” in MS and fibromyalgia reflects narrative citations of prior literature rather than any quantitative synthesis of the 47 included trials. The authors themselves acknowledge that the lack of standardized dosing, outcome measures, and study protocols across trials represents the central barrier to clinical translation, and they call for harmonized research designs before treatment recommendations can be made.

Dr. Caplan’s Take

This review does something genuinely useful: it shows us the shape of the clinical trial landscape for cannabinoids in neurology. Knowing that most completed work clusters in Phase 2, that MS and fibromyalgia dominate, and that outcome measures are fragmented gives researchers and clinicians a clearer picture of where we are. But the gap between a landscape map and actionable clinical evidence is enormous. When patients with Parkinson’s or MS ask whether cannabinoids can help their symptoms, I have to be honest that the trial activity they may have read about does not yet translate into validated treatment protocols.

In practice, I approach cannabinoid discussions with neurological patients by acknowledging the biological plausibility and the early clinical signals while being transparent about what we do not yet know. For patients already using cannabinoid products, I focus on safety monitoring, potential drug interactions with their existing neurological medications, and realistic expectations. I do not discourage interest, but I frame cannabinoids as an area of active investigation rather than established therapy, and I prioritize evidence-based treatments as the foundation of any neurological care plan.

Clinical Perspective

This review sits very early in the research arc. It maps trial registrations rather than synthesizing published outcomes, placing it before even the stage at which systematic reviews with meta-analysis would operate. For clinicians, its value is contextual rather than directive: it confirms that cannabinoid research in neurology is expanding but remains methodologically immature, with most trials in Phase 2 and no standardized approaches to dosing or outcome measurement. The review does not provide the evidentiary basis to recommend cannabinoids for any specific neurological condition, nor does it refute their potential. It simply documents a field in transition.

Clinicians should be particularly attentive to pharmacological considerations when neurological patients inquire about cannabinoids. Both THC and CBD interact with cytochrome P450 enzymes, notably CYP3A4 and CYP2C19, creating potential interactions with commonly prescribed neurological medications including antiepileptic drugs such as clobazam and valproate, as well as certain disease-modifying therapies. The most actionable step clinicians can take now is to systematically ask neurological patients about cannabinoid use, document it, monitor for interactions with existing medications, and set expectations that current evidence supports continued investigation but not yet clinical adoption as standard therapy.

Study at a Glance

Study Type

Registry-based systematic mapping review

Population

Patients with neurological conditions enrolled in completed clinical trials

Intervention

Cannabinoids (primarily THC and CBD) as primary intervention

Comparator

Varied across trials; not pooled

Primary Outcomes

Pain management, spasticity, and cognitive function

Sample Size

47 completed trials included from 132 cannabinoid-relevant neurological trials

Journal

Not specified in source data

Year

2025

DOI or PMID

Not available

Funding Source

Not reported

What Kind of Evidence Is This

This is a registry-based scoping or mapping review that searched a single clinical trial registry, ClinicalTrials.gov, to characterize the landscape of completed cannabinoid trials in neurological conditions. It occupies a position below traditional systematic reviews and well below meta-analyses in the evidence hierarchy. The most important inference constraint is that because no trial results were pooled and no risk-of-bias assessment was conducted, the review cannot establish, quantify, or even reliably suggest the efficacy of cannabinoids for any neurological condition.

How This Fits With the Broader Literature

The review’s findings are broadly consistent with prior Cochrane and systematic reviews that have examined cannabinoids in specific neurological conditions. For example, Cochrane reviews of cannabinoids for MS-related spasticity and the well-established evidence base for CBD in treatment-resistant epilepsy (notably Dravet and Lennox-Gastaut syndromes) confirm that a few narrow applications have stronger support than others. What this mapping review adds is a bird’s-eye view showing that beyond these better-studied areas, the trial landscape is thin and methodologically fragmented. It extends prior work by documenting the breadth of conditions under investigation while simultaneously reinforcing the recurring finding that standardization remains the field’s most critical unmet need.

Common Misreadings

The most likely overinterpretation is reading this review as evidence that cannabinoids are “promising” or “effective” for neurological conditions based on 47 completed trials. The review catalogs trial registrations; it does not extract, analyze, or synthesize their results. The authors’ references to “promising results” derive from narrative citations of previously published literature, not from any findings generated by this review itself. Treating a landscape map as a body of positive evidence fundamentally exceeds what this document can support and could mislead both clinicians and patients about the current state of knowledge.

Bottom Line

This review provides a useful inventory of where cannabinoid trial activity in neurology is concentrated and where methodological gaps are most acute. It does not establish efficacy for any condition. The field remains in early-to-intermediate clinical development, dominated by Phase 2 trials with inconsistent designs. For clinical practice today, it reinforces the need for honest patient conversations, safety monitoring, and the recognition that robust treatment recommendations await standardized, adequately powered trials with pooled outcome data.

References

1. Registry-based systematic mapping review of cannabinoid clinical trials for neurological disorders, ClinicalTrials.gov analysis, 2025. Full citation details not available from source data.
2. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358
3. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011-2020. doi:10.1056/NEJMoa1611618
4. Nielsen S, Germanos R, Weier M, et al. The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews. Curr Neurol Neurosci Rep. 2018;18(2):8. doi:10.1007/s11910-018-0814-x